AgomAb Therapeutics (NASDAQ:AGMB) Now Covered by HC Wainwright

Analysts at HC Wainwright started coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a report released on Monday,Benzinga reports. The firm set a “buy” rating on the stock.

Several other research analysts have also recently commented on AGMB. JPMorgan Chase & Co. started coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They issued an “overweight” rating and a $32.00 price target on the stock. Morgan Stanley began coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 price objective for the company. Leerink Partners started coverage on AgomAb Therapeutics in a report on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 price objective on the stock. Finally, Zacks Research upgraded AgomAb Therapeutics to a “hold” rating in a research note on Wednesday, March 4th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, AgomAb Therapeutics has an average rating of “Moderate Buy” and an average target price of $32.00.

AgomAb Therapeutics Price Performance

NASDAQ:AGMB opened at $10.98 on Monday. The firm has a 50-day moving average price of $10.96. AgomAb Therapeutics has a 1-year low of $8.75 and a 1-year high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.